EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

BRAF V600E immunohistochemistry can reliably substitute BRAF molecular testing in the Lynch syndrome screening algorithm in colorectal cancer

Federica Grillo iD, Michele Paudice, Simona Pigozzi, Maria Dono, Sonia Lastraioli, Marialuisa Lugaresi, Silvia Bozzano, Camilla Tognoni, Murad Ali, Stefania Sciallero, Alberto Puccini, Matteo Fassan iD und 1 weitere

Histopathology · 2024

DOI: 10.1111/his.15133 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Histopathology, 2024. Verfasst von Federica Grillo und 12 weiteren Autor:innen. Beteiligte Einrichtung: IRCCS Ospedale Policlinico San Martino, Genoa, Italy. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Hereditary Nonpolyposis, Colorectal Neoplasms, Brain Neoplasms, Neoplastic Syndromes, Hereditary. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

The Lynch syndrome (LS) screening algorithm requires BRAF testing as a fundamental step to distinguish sporadic from LS‐associated colorectal carcinomas (CRC). BRAF testing by immunohistochemistry (IHC) has shown variable results in the literature. Our aim was to analyse concordance between BRAF V600E IHC and BRAF molecular analysis in a large, mono‐institutional CRC whole‐slide, case series with laboratory validation. Methods and results MisMatch repair (MMR) protein (hMLH1, hPMS2, hMSH2, and hMSH6) and BRAF V600E IHC were performed on all unselected cases of surgically resected CRCs (2018–2023). An in‐house validation study for BRAF V600E IHC was performed in order to obtain optimal IHC stains. BRAFV V600E IHC was considered negative (score 0), positive (scores 2–3), and equivocal (score 1). Interobserver differences in BRAF V600E IHC scoring were noted in the first 150 cases prospectively collected. Nine‐hundred and ninety CRCs cases (830 proficient (p)MMR/160 deficient (d)MMR) were included and all cases performed BRAF V600E IHC (BRAF V600E IHC‐positive 13.5% of all series; 66.3% dMMR cases; 3.4% pMMR cases), while 333 also went to BRAF mutation analysis. Optimal agreement in IHC scoring between pathologists ( P < 0.0001) was seen; concordance between BRAF V600E IHC and BRAF molecular analysis was extremely high (sensitivity 99.1%, specificity 99.5%; PPV 99.1%, and NPV 99.5%). Discordant cases were reevaluated; 1 score 3 + IHC/wildtype case was an interpretation error and one score 0 IHC/mutated case was related to heterogenous BRAF V600E IHC expression. Among the 12 IHC‐equivocal score 1+ cases (which require BRAF molecular analysis), three were BRAF‐ mutated and nine BRAF‐ wildtype.

Conclusion

BRAF V600E IHC can be used as a reliable surrogate of molecular testing after stringent in‐house validation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Colorectal Neoplasms, Hereditary NonpolyposisColorectal NeoplasmsBrain NeoplasmsNeoplastic Syndromes, HereditaryHumansImmunohistochemistryProto-Oncogene Proteins B-rafEarly Detection of CancerMolecular Diagnostic TechniquesAlgorithmsDNA Mismatch RepairMutation

Stichwörter der Autor:innen

BRAFLynch syndromecolorectal cancerimmunohistochemistry

Substanzen

Proto-Oncogene Proteins B-rafBRAF protein, human

Autor:innen und Institutionen

  • IRCCS Ospedale Policlinico San Martino, Genoa, Italy.
  • Pathology Unit, Department of Surgical Sciences and Integrated Diagnostics (DISC), University of Genoa, Genoa, Italy.
  • Molecular Diagnostic Unit, IRCCS Ospedale Policlinico San Martino, Genoa, Italy.
  • Department of Medical and Surgical Sciences (DIMEC), Alma Mater Studiorum, University of Bologna, Bologna, Italy.
  • Division of Thoracic Surgery, Maria Cecilia Hospital, GVM Care & Research Group, Ravenna, Italy.
  • Medical Oncology Unit 1, IRCCS Ospedale Policlinico San Martino, Genoa, Italy.

ORCID-Profile: Federica Grillo, Matteo Fassan

Zitieren

APA

Grillo, F., Paudice, M., Pigozzi, S., Dono, M., Lastraioli, S., Lugaresi, M., Bozzano, S., Tognoni, C., Ali, M., Sciallero, S., Puccini, A., Fassan, M., & Mastracci, L. (2024). BRAF V600E immunohistochemistry can reliably substitute BRAF molecular testing in the Lynch syndrome screening algorithm in colorectal cancer. Histopathology. https://doi.org/10.1111/his.15133

Vancouver

Grillo F, Paudice M, Pigozzi S, Dono M, Lastraioli S, Lugaresi M, et al. BRAF V600E immunohistochemistry can reliably substitute BRAF molecular testing in the Lynch syndrome screening algorithm in colorectal cancer. Histopathology. 2024. doi:10.1111/his.15133

BibTeX
@article{Grillo2024,
  author = {Grillo, Federica and Paudice, Michele and Pigozzi, Simona and Dono, Maria and Lastraioli, Sonia and Lugaresi, Marialuisa and Bozzano, Silvia and Tognoni, Camilla and Ali, Murad and Sciallero, Stefania and Puccini, Alberto and Fassan, Matteo and Mastracci, Luca},
  title = {BRAF V600E immunohistochemistry can reliably substitute BRAF molecular testing in the Lynch syndrome screening algorithm in colorectal cancer},
  journal = {Histopathology},
  year = {2024},
  doi = {10.1111/his.15133}
}
Kostenlos starten →